Moderna seeks full rego for Spikevax

Moderna’s Spikevax is set to be the first of Australia’s provisionally approved COVID-19 vaccines to undergo an evaluation to transition to full registration.  The Therapeutic Goods Administration (TGA) revealed Moderna Australia has lodged an application for the vaccine to be granted full market authorisation for the immunisation of individuals aged six years and older, and